Biotech Startups

Cytoki is a biotech company developing IL-22-based therapeutics using lipidation technology to treat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease. It focuses on drug discovery and clinical development for these indications.

2 investors

Cytos is an orthobiologics company that develops biologic treatments for orthopedic conditions. The company serves orthopedic surgeons and patients requiring spine, foot, ankle, and other orthopedic interventions.

2 investors

Cytotrait develops genetic technologies for crop improvement through chloroplast engineering. The company applies proprietary MOSS technology to enable precise DNA mutagenesis in plant genomes for agricultural biotechnology applications.

2 investors

Dalan develops vaccines that work with animals' natural immune defenses to protect against disease, with products including a USDA-approved honeybee vaccine and a shrimp vaccine in development. The company operates in the bioscience and animal health sector, serving agriculture and aquaculture markets.

2 investors

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

2 investors

Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.

2 investors

Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits. Its platform focuses on day-to-day health management for individuals with one or more chronic conditions, primarily in the U.S.

2 investors

DataJoint builds data platforms and infrastructure for scientific operations, enabling researchers and organizations to create reproducible, scalable, and traceable research workflows powered by AI and automation.

2 investors

DSI provides scientific services for preclinical research, including implanted telemetry support, in vivo study execution, data analysis and reporting, and GLP validation. It serves researchers and laboratories conducting physiological studies such as cardiovascular and respiratory monitoring in animal models.

2 investors

The page is a bioMérieux blog article about tracking a Cyclospora cayetanensis outbreak in the United States, referencing its clinical diagnostic and wastewater surveillance products for community health and medical professionals.

2 investors

Decameal converts invasive crab into high-value ingredients such as protein, chitosan, and astaxanthin, operating a pilot production and laboratories to validate the value chain from fisherman to finished feed. The company develops sustainable extraction methods aimed at restoring marine ecosystems and supplying food and feed ingredients, based in Denmark.

2 investors

Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.

2 investors

deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer. The company serves pharmaceutical and research organizations through genomic discovery and analysis.

2 investors

DEEP Measures enables the adoption of harmonized digital health measures across the pharmaceutical, tech, and regulatory ecosystem. The company connects pharma companies, technology providers, and regulators to collaboratively develop and deploy digital solutions for clinical research and health measurement.

2 investors

Delineate builds AI agents that help pharmaceutical companies design clinical trials more quickly by converting existing trial research into specialized datasets, reducing the time scientists spend on trial preparation.

2 investors

Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.

2 investors

Delta Life Science develops the inQuiQ, a label-free biosensing instrument that uses integrated photonics to measure biomolecular binding affinity and kinetics (KD, ka, kd) in real time from small sample volumes. It serves academic research institutes, biotech R&D, and CROs/CDMOs as an alternative to surface plasmon resonance and bio-layer interferometry for applications such as antibody characterization, small molecule and fragment screening, and PROTAC/molecular glue analysis.

2 investors

DEMECAN produces and distributes medical cannabis products, including cannabis-containing medicines and extracts used to make capsules, which pharmacies can order directly. It provides information for patients and doctors on cannabis therapy and operates in Germany.

2 investors

Denovo Sciences develops an AI platform for structure-based small-molecule drug discovery, using generative algorithms to design candidate molecules de novo within a target's binding pocket and predict their synthesizability and drug-likeness. It runs its own drug discovery programs and partners with others to identify small-molecule drug candidates, including work on broad-spectrum influenza inhibitors.

2 investors

Dia Beta Labs is a drug discovery and development company focused on diabetes and obesity research. The company leverages academic expertise and scientific innovation in these therapeutic areas.

2 investors

Diadem is a diagnostics company developing AlzoSure, a plasma/blood-based test that uses a proprietary antibody targeting a specific conformation of the p53 protein to predict and diagnose Alzheimer's disease. The test aims to provide early, non-invasive diagnosis and to support patient recruitment for Alzheimer's drug development clinical trials.

2 investors

Diadem Bio develops therapeutic treatments designed to be safe, powerful, versatile and cost-effective for patients with unmet medical needs, with a focus on potential cancer cures and other difficult diseases.

2 investors

Hologic Diagenode provides epigenomics profiling services and sample preparation products for next-generation sequencing, proteomics, and epigenetics research. It serves biomarker discovery and validation through epigenomics and bioinformatics for research applications.

2 investors

Dialybrid develops vascular grafts for hemodialysis using Silkothane®, a hybrid material combining silk fibroin and polyurethane, targeting nephrologists and dialysis centers. The company focuses on advanced biomedical devices in the tissue engineering and regenerative medicine sector.

2 investors